FDA Advisory Panel Unanimously Backs Moderna's mRNA Flu Vaccine for Adults 50 and Older

FDA Committee Gives Unanimous Green Light to Moderna's mRNA Flu Vaccine

In a unanimous 9-0 decision, the Food and Drug Administration's premier vaccine advisory body has recommended approval of Moderna's mRNA-based influenza vaccine, known as mFlusiva, for adults aged 50 and older. The vote marks the first time the Vaccines and Related Biological Products Advisory Committee (VRBPAC) has reviewed a new vaccine application since May 2023 — a gap of more than three years.

A Breakthrough Amid Political Headwinds

The recommendation carries significant weight given the current political climate surrounding vaccines. Under the second Trump administration, both President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. have been vocal critics of vaccine programs, particularly those utilizing mRNA technology. Kennedy previously pulled back nearly $500 million in federal contracts earmarked for mRNA vaccine development.

Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia and a former FDA advisory panel member, called the vote a welcome relief. "It's such a breath of fresh air, considering what we've gone through with Robert F. Kennedy Jr.," he said.

The path to this vote was not without obstacles. The FDA initially declined to review Moderna's application earlier this year, only to reverse that decision within two weeks following widespread criticism from the public health community.

How the mRNA Flu Vaccine Works

Moderna's mFlusiva uses the same messenger-RNA technology that underpinned the development of COVID-19 vaccines. Rather than introducing weakened or inactivated flu particles into the body, mRNA instructs human cells to produce flu antigens, prompting the immune system to build defenses. The vaccine covers three to four influenza strains and delivers an amount of mRNA so minuscule it is comparable in weight to the trace left by a fingerprint on a mirror.

Importantly, Moderna confirmed that the vaccine "does not enter the cellular nucleus, does not interact with the genome, and does not persist in the body" — directly addressing widespread misinformation that has fueled public skepticism.

Why Experts Are Excited About mRNA Flu Technology

Beyond the immediate health benefits, public health specialists are enthusiastic about mRNA flu vaccines for practical reasons. Traditional flu vaccines can take up to six months to manufacture and distribute once a new strain is identified. The mRNA platform could slash that timeline to just two to three months — the same compressed schedule demonstrated during the COVID-19 pandemic — dramatically improving the vaccine's relevance when a novel or mismatched flu strain emerges.

Dr. Evan Anderson, vice president of epidemiology at Moderna, highlighted the problem of strain mismatch in existing flu vaccines and emphasized that the faster production window of mRNA technology could significantly boost vaccine accuracy and effectiveness each season.

Stronger, Longer-Lasting Protection

Research published in both the New England Journal of Medicine and Nature Immunology provided compelling evidence for the vaccine's superiority over standard flu shots. Hanover Matz, a postdoctoral researcher at Washington University in St. Louis, and his team analyzed immune responses from 75 trial participants, focusing not just on the quantity of antibodies produced but on their quality and breadth.

"It's not something that is typically evaluated when anybody looks at vaccine research," Matz noted. Their findings revealed that the mRNA vaccine generated a more durable immune response and antibodies capable of recognizing a broader range of flu strains — a potential explanation for why it may outperform conventional flu vaccines.

Dr. Anna Durbin, director of the Center for Immunization Research at Johns Hopkins University and a VRBPAC member, emphasized the rigor of Moderna's clinical program. "There were no shortcuts taken. There was a full efficacy evaluation done per standard FDA guidance — phase 3 efficacy studies conducted in tens of thousands of individuals," she told NPR.

Safety Profile Deemed Highly Favorable

Despite lingering public concerns about mRNA vaccines, Thursday's six-and-a-half-hour review found no major safety issues. Dr. Gauri Raval, a medical officer in the FDA's Division of Clinical and Toxicology Review, stated that the Moderna mRNA flu vaccine "may offer greater efficacy than the standard dose comparator in preventing more severe influenza-associated illnesses," with no significant safety deficiencies identified.

Dr. Jesse Goodman, former director of the FDA's Center for Biologics Evaluation and Research, acknowledged the heavy politicization of mRNA vaccines but was firm in his assessment. Claims that mRNA vaccines cause cancer or alter DNA are "not possible and disproven," he said. Dr. Durbin reinforced this, pointing to the more than 6 billion mRNA vaccine doses administered globally since 2020, describing their safety record as "incredibly strong" with no evidence of DNA integration.

"The mRNA platform has really been a game changer for vaccines, and it's an incredibly important advancement in medical science," Durbin said. "We have to do a much better job of educating the public around that, but I have the highest confidence in the vaccine."

The Flu Burden: Why This Matters Now

The urgency of this recommendation is underscored by the scale of influenza's impact. Dr. Lisa Grohskopf of the CDC presented data showing that the 2025-2026 flu season alone has resulted in at least 32 million cases, 390,000 hospitalizations, and 24,000 deaths in the United States. Compounding the crisis, approximately 85% of those eligible for flu vaccination remain inadequately protected.

Calls for Greater FDA Advisory Activity

The meeting also prompted broader calls for the FDA to convene its advisory committees more frequently. Michael Abrams, a senior researcher at the nonprofit Public Citizen, urged the agency to make fuller use of expert panels that have been underutilized since January 2025. Historically, between 2000 and 2019, the VRBPAC reviewed approximately one new vaccine application per year — a pace that has slowed dramatically in recent years.

Dr. Durbin noted that a routine spring flu meeting that typically takes place annually was skipped entirely in 2025. She expressed even greater concern about the CDC's Advisory Committee on Immunization Practices (ACIP), which she described as having a different but equally critical role. "ACIP has a different purpose than VRBPAC — they will determine how these vaccines are used," she explained.

Dr. Goodman expressed cautious optimism about the day's proceedings. "I'm encouraged that this is happening, and in what appears to be a balanced way that's paying attention to the feedback of FDA vaccine experts and outside experts who really wanted to see this vaccine reviewed in the light of day."

What Comes Next

Thursday's committee vote is a recommendation, not a final approval — the FDA will make its ultimate decision independently. However, the agency typically follows the guidance of its advisory panels, meaning mFlusiva may be on the verge of becoming the first vaccine approved under the current administration. If cleared, it could represent a turning point not only for flu prevention but for the broader future of mRNA-based medicine in the United States.